des-Arginine Complement C5a

A derivative of complement C5a, generated when the carboxy-terminal ARGININE is removed by CARBOXYPEPTIDASE B present in normal human serum. C5a des-Arg shows complete loss of spasmogenic activity though it retains some chemotactic ability (CHEMOATTRACTANTS).

Also Known As:

Complement C5a, des-Arginine; C5 a, des-Arg; C5 a, des-Arginine; C5a des-Arg; C5a des-Arginine; C5a, des-Arg; C5a, des-Arginine; Complement 5a, de-Arginine; Complement 5a, des-Arginine; C5 a, des Arg; C5 a, des Arginine; C5a des Arginine; C5a, des Arg; C5a, des Arginine; C5a, des-Arginine Complement; Complement 5a, de Arginine; Complement 5a, des Arginine; Complement C5a, des Arginine; de-Arginine Complement 5a; des-Arg C5 a; des-Arg C5a; des-Arg, C5a; des-Arginine C5 a; des-Arginine C5a; des-Arginine Complement 5a; des-Arginine, C5a

Networked: 35 relevant articles (1 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Immunoproteins: 43
      - Complement System Proteins: 33379
        Anaphylatoxins: 563
        Complement C5a: 190
        des-Arginine Complement C5a: 35
        Complement C5: 270
        Complement C5a: 190
        des-Arginine Complement C5a: 35

Experts

1.	Heuertz, Rita M: 1 article (12/2005)
2.	Nash, Steven P: 1 article (12/2005)
3.	Abe, M: 1 article (09/2000)
4.	Hugli, T E: 1 article (09/2000)
5.	Kamiya, H: 1 article (09/2000)
6.	Katsuragi, T: 1 article (09/2000)
7.	Kodani, M: 1 article (09/2000)
8.	Sakata, N: 1 article (09/2000)
9.	Takano, Y: 1 article (09/2000)

Related Diseases

1.	Pneumonia (Pneumonitis) 07/01/1980 - "Because C5a is rapidly converted to C5a des Arg in vivo, experiments were performed to determine which fragment was most effective in producing pulmonary inflammation in this animal model. " 07/01/1980 - "A differential effect of C5a and C5a des Arg in the induction of pulmonary inflammation."
2.	Sepsis (Septicemia) 06/01/1986 - "This study demonstrates that treatment with rabbit anti-human C5a des arg antibodies attenuates ARDS and some of the systemic manifestations of sepsis in nonhuman primates." 01/01/1985 - "The rise in C3b receptor number was ascribed to up-regulation by C3a and C5a des Arg from complement activation and also, in the cases where sepsis occurred, to the presence of bacterial chemotactic peptides. " 11/01/1984 - "To determine if biologically active products of complement appear during sepsis and to establish the relationship of these components to the respiratory and hemodynamic complications of sepsis, we measured C5a des Arg and C3a des Arg (radioimmunoassay), neutrophil chemotaxis, and neutrophil-aggregating activity in plasma obtained from 40 patients at the time sepsis was suspected clinically. " 10/01/1992 - "To provide information about the clinical importance of such events in sepsis, different complement parameters (C3, C4, and the desarginated forms of C3a [C3a(des)-Arg] and C5a [C5a(des)-Arg]), PMN elastase, and malondialdehyde (a by-product of membrane peroxidation by oxygen radicals) were measured daily in 26 septic patients and correlated with two objectively assessed and previously validated severity scores (acute physiology and chronic health evaluation [APACHE II] and Sepsis Severity Score [SSS]). "
3.	Trichosporonosis 05/01/1989 - "A previous study demonstrated increased levels of C5a des Arg and increased numbers of polymorphonuclear cells (PMNs) in bronchoalveolar lavage (BAL) fluids of acutely ill patients with summer type hypersensitivity pneumonitis (HP), suggesting the role of immune complexes (IC) in the early stage of HP. "
4.	Acute Lung Injury 12/01/2005 - "In this study, mice received an oral dose (100 mg/kg) of the p38 MAPK inhibitor, SB203580, followed by intratracheal instillation of an agent of complement origin, C5a des arg, at a concentration (10 microg) that induced acute lung injury. "
5.	Myocardial Ischemia (Ischemic Heart Diseases) 07/01/1991 - "Although previous studies have demonstrated that complement (C)5a causes myocardial ischemia and mechanical dysfunction, the cardiac response of endogenously produced C5a and C5a des-Arg in zymosan-activated serum (ZAS) and the critical role of granulocytes in this process are poorly understood. "

Related Drugs and Biologics

1.	Complement System Proteins (Complement)
2.	Antigen-Antibody Complex (Immune Complex)
3.	Zymosan
4.	des-Arg-(77)- complement C3a
5.	p38 Mitogen-Activated Protein Kinases
6.	Anti-Allergic Agents (Antiallergic Agents)
7.	Antibodies
8.	SB 203580
9.	Anaphylatoxins
10.	Leukotriene B4

Related Therapies and Procedures

1.	Artificial Respiration (Mechanical Ventilation)
2.	Intravenous Infusions